Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
International Journal of Pediatrics ; (6): 231-234, 2020.
Article in Chinese | WPRIM | ID: wpr-862967

ABSTRACT

Hypertrophic cardiomyopathy(HCM)is a cardiac disease characterized by left ventricular cardiac hypertrophy, which is the most common hereditary cardiovascular disease, accounting for the second in childhood cardiomyopathy.Currently, drug therapy for HCM mainly includes beta blockers, calcium channel blockers, antiarrhythmic drugs and novel drugs, whose main effect is to delay symptoms.However, because the causes of HCM in children are more complex than in adults, so the treatment is more challenging.And the genetic metabolic defect is one of the most common causes of HCM in children.In view of this kind of etiology, drug therapy that mainly regulates metabolic abnormalities is more important.Some children with HCM can significantly improve cardiac function and even reverse cardiomyopathy through early intervention.Here we review the progress of drug therapy for HCM in children.

SELECTION OF CITATIONS
SEARCH DETAIL